Cullinan Therapeutics, Inc.
CGEM
$8.71
$0.202.35%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.12% | 10.97% | 7.87% | 2.67% | 4.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.29% | 4.22% | 11.27% | 5.13% | 43.95% |
| Operating Income | -3.29% | -4.22% | -11.27% | -5.13% | -43.95% |
| Income Before Tax | 1.04% | -0.71% | -7.85% | -218.14% | -211.83% |
| Income Tax Expenses | 100.83% | -660.06% | -222.35% | -122.89% | -133.53% |
| Earnings from Continuing Operations | -8.04% | 7.11% | -1.25% | -310.02% | -242.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -90.10% | 302.47% | 241.86% | 39.03% | -3.96% |
| Net Income | -9.28% | 8.07% | -0.28% | -302.52% | -237.72% |
| EBIT | -3.29% | -4.22% | -11.27% | -5.13% | -43.95% |
| EBITDA | -3.30% | -4.22% | -11.23% | -5.04% | -43.82% |
| EPS Basic | 15.34% | 22.90% | 7.74% | -333.93% | -248.40% |
| Normalized Basic EPS | 21.66% | 16.30% | 2.85% | -0.01% | -47.21% |
| EPS Diluted | 15.34% | 22.94% | 7.80% | -358.90% | -256.53% |
| Normalized Diluted EPS | 21.66% | 16.30% | 2.85% | -0.72% | -48.54% |
| Average Basic Shares Outstanding | 29.38% | 17.78% | 6.74% | -4.76% | -8.03% |
| Average Diluted Shares Outstanding | 29.38% | 17.78% | 6.74% | -5.57% | -8.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
